inclusion criteria: 1. t2dm according to the ada criteria. patients with long standing diabetes as well as patients with new onset diabetes will be recruited. patients receiving glucocorticoids for treatment of covid-19 and manifest plasma glucose levels consistent with diabetes diagnosis also will be included 2. patients can be drug naïve, receiving oral antihyperglycemic therapy (except pioglitazone), glp-1 ra or insulin therapy will be allowed to participate in the study 3. covid-19 infection confirmed with pcr test 4. age 21-85 years 5. patients of both sexes will be included 6. in addition to diabetes and covid-19 diagnoses, patients should manifest at least one of covid-19 symptoms (fever, chills, headache, rhinorreah, cough (dry or with sputum), sore throat, shortness of breath, hemoptysis, altered mentation, fatigue/malaise, myalgia, nausea/vomiting, diarrhea, anosmia, chest pain). 7. patient receiving other anti-inflammatory therapy for their routine covid-19 care (e.g. hydroxychloroquine), or antiviral therapy (e.g. remdesivire) will be included in the study and will be evenly randomized amongst the two treatment groups

inclusion criteria: 1. t2dm according to the ada criteria. patients with long standing diabetes as well as patients with new onset diabetes will be recruited. patients receiving glucocorticoids for treatment of covid-19 and manifest plasma glucose levels consistent with diabetes diagnosis also will be included 2. patients can be drug naïve, receiving oral antihyperglycemic therapy (except pioglitazone), glp-1 ra or insulin therapy will be allowed to participate in the study 3. covid-19 infection confirmed with pcr test 4. age 21-85 years 5. patients of both sexes will be included 6. in addition to diabetes and covid-19 diagnoses, patients should manifest at least one of covid-19 symptoms (fever, chills, headache, rhinorreah, cough (dry or with sputum), sore throat, shortness of breath, hemoptysis, altered mentation, fatigue/malaise, myalgia, nausea/vomiting, diarrhea, anosmia, chest pain). 7. patient receiving other anti-inflammatory therapy for their routine covid-19 care (e.g. hydroxychloroquine), or antiviral therapy (e.g. remdesivire) will be included in the study and will be evenly randomized amongst the two treatment groups

inclusion criteria: t2dm according to the ada criteria. patients with long standing diabetes as well as patients with new onset diabetes will be recruited. patients receiving glucocorticoids for treatment of covid-19 and manifest plasma glucose levels consistent with diabetes diagnosis also will be included patients can be drug naïve, receiving oral antihyperglycemic therapy (except pioglitazone), glp-1 ra or insulin therapy will be allowed to participate in the study covid-19 infection confirmed with pcr test age 21-85 years patients of both sexes will be included in addition to diabetes and covid-19 diagnoses, patients should manifest at least one of covid-19 symptoms (fever, chills, headache, rhinorreah, cough (dry or with sputum), sore throat, shortness of breath, hemoptysis, altered mentation, fatigue/malaise, myalgia, nausea/vomiting, diarrhea, anosmia, chest pain). patient receiving other anti-inflammatory therapy for their routine covid-19 care (e.g. hydroxychloroquine), or antiviral therapy (e.g. remdesivire) will be included in the study and will be evenly randomized amongst the two treatment groups

inclusion criteria: t2dm according to the ada criteria. patients with long standing diabetes as well as patients with new onset diabetes will be recruited. patients receiving glucocorticoids for treatment of covid-19 and manifest plasma glucose levels consistent with diabetes diagnosis also will be included patients can be drug naïve, receiving oral antihyperglycemic therapy (except pioglitazone), glp-1 ra or insulin therapy will be allowed to participate in the study covid-19 infection confirmed with pcr test age 21-85 years patients of both sexes will be included in addition to diabetes and covid-19 diagnoses, patients should manifest at least one of covid-19 symptoms (fever, chills, headache, rhinorreah, cough (dry or with sputum), sore throat, shortness of breath, hemoptysis, altered mentation, fatigue/malaise, myalgia, nausea/vomiting, diarrhea, anosmia, chest pain). patient receiving other anti-inflammatory therapy for their routine covid-19 care (e.g. hydroxychloroquine), or antiviral therapy (e.g. remdesivire) will be included in the study and will be evenly randomized amongst the two treatment groups

inclusion criteria: 1. t2dm according to the ada criteria. patients with long standing diabetes as well as patients with new onset diabetes will be recruited. patients receiving glucocorticoids for treatment of covid-19 and manifest plasma glucose levels consistent with diabetes diagnosis also will be included 2. patients can be drug naïve, receiving oral antihyperglycemic therapy (except pioglitazone), glp-1 ra or insulin therapy will be allowed to participate in the study 3. covid-19 infection confirmed with pcr test 4. age 21-85 years 5. patients of both sexes will be included 6. in addition to diabetes and covid-19 diagnoses, patients should manifest at least one of covid-19 symptoms (fever, chills, headache, rhinorreah, cough (dry or with sputum), sore throat, shortness of breath, hemoptysis, altered mentation, fatigue/malaise, myalgia, nausea/vomiting, diarrhea, anosmia, chest pain). 7. patient receiving other anti-inflammatory therapy for their routine covid-19 care (e.g. hydroxychloroquine), or antiviral therapy (e.g. remdesivire) will be included in the study and will be evenly randomized amongst the two treatment groups

inclusion criteria: 1. t2dm according to the ada criteria. patients with long standing diabetes as well as patients with new onset diabetes will be recruited. patients receiving glucocorticoids for treatment of covid-19 and manifest plasma glucose levels consistent with diabetes diagnosis also will be included 2. patients can be drug naïve, receiving oral antihyperglycemic therapy (except pioglitazone), glp-1 ra or insulin therapy will be allowed to participate in the study 3. covid-19 infection confirmed with pcr test 4. age 21-85 years 5. patients of both sexes will be included 6. in addition to diabetes and covid-19 diagnoses, patients should manifest at least one of covid-19 symptoms (fever, chills, headache, rhinorreah, cough (dry or with sputum), sore throat, shortness of breath, hemoptysis, altered mentation, fatigue/malaise, myalgia, nausea/vomiting, diarrhea, anosmia, chest pain). 7. patient receiving other anti-inflammatory therapy for their routine covid-19 care (e.g. hydroxychloroquine), or antiviral therapy (e.g. remdesivire) will be included in the study and will be evenly randomized amongst the two treatment groups